Analysts Are Gushing Over Novo Nordisk A/S (NVO), BioCryst Pharmaceuticals, Inc. (BCRX)

Novo Nordisk A/S (NYSE:NVO) last session’s volume of 1.12 million shares was lower than its average volume of 1.98 million shares. The stock, after opening at $50.63, hit $50.91 through the close by scoring 0.81%.

Novo Nordisk A/S (NVO) Analyst Opinion

Novo Nordisk A/S has a consensus hold rating from 1 Wall Street analysts, and the number of shares currently sold short amount to at least 0.32% of shares outstanding. The stock spiked 0.45% last month and is up 41.97 this year. Wall Street is only getting neutral on the stock, with 0 of analysts who cover NVO having a buy-equivalent rating. Analysts have placed a $51.35 price target on Novo Nordisk A/S, suggesting a 0.86% gain from recent close. It’s currently trading about -0.08% below its 52-week high.

Novo Nordisk A/S Earnings Surprise

Novo Nordisk A/S (NVO) surprised the stock market in its last reported earnings when it earned $0.63 a piece versus the consensus-estimated $0.61. Its revenue totaled $4.35 billion up 2.95% from the previous quarter.

Novo Nordisk A/S (NYSE:NVO) Intraday View

This stock (NVO) is ahead of its 52-week low with 64.81%. Its last month’s stock price volatility remained 0.82% which for the week stands at 1.04%. The share price has moved forward from its 20 days moving average, trading at a distance of 2.13% and stays 3.37% away from its 50 days moving average. Over the last five days, shares have managed 2% gains and now is up 20.54% since hitting its 200-day moving average of $45.28. Novo Nordisk A/S (NVO) has made its way to a 12-month gain of 55.02%.

Turning to BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), its shares were trading at $4.52 a retreat of $-0.11, on the trading floor. The stock, after opening at $4.61, touched a high of $4.7 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.2. BioCryst Pharmaceuticals, Inc. has 2 buy ratings, 2 holds and 0 sells even after the stock tumbled -51.14% from its high of $9.25 to a $366.03 million market value through last close.

BioCryst Pharmaceuticals, Inc. (BCRX) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 2.2 to 2.2 during a month. Analysts set a 12-month price target of $8.56 a share. The target implies a 89.38% spike from where the shares are currently trading. Also, the current price highlights a discount of 165.49% to analysts’ high consensus price target.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Intraday Trading

The counter witnessed a trading volume of 2.3 million shares versus an average volume of 1.63 million shares during last trading session. Its last month’s stock price volatility remained 4.35% which for the week approaches 5.32%. The lowest price the stock reached in the last trading day was $4.43 and compares with the $3.95 52-week low. The stock recovered 14.43% since its low point and has performed -28.59% year-to-date.

Previous articleAnalysts Give These Stocks Mix Nod: Raytheon Company (RTN), Cymabay Therapeutics, Inc. (CBAY)
Next articleStreet Analysts View On SAP SE (SAP), AVEO Pharmaceuticals, Inc. (AVEO)